Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

23.95USD
17 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$23.95
Open
$23.80
Day's High
$24.15
Day's Low
$23.50
Volume
73,560
Avg. Vol
130,544
52-wk High
$27.90
52-wk Low
$14.95

Latest Key Developments (Source: Significant Developments)

Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
Monday, 6 Nov 2017 04:15pm EST 

Nov 6 (Reuters) - Lannett Company Inc :Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance.Q1 adjusted earnings per share $0.60.Q1 earnings per share $0.35.Q1 earnings per share view $0.52 -- Thomson Reuters I/B/E/S.Q1 sales $155 million versus I/B/E/S view $153.6 million.Lannett Company Inc sees fiscal 2018 ‍net sales of $710 million to $720 million, up from $655 million to $665 million​.Lannett Company Inc sees fiscal 2018 ‍capital expenditures of $65 million to $75 million.Q1 revenue view $153.6 million -- Thomson Reuters I/B/E/S.FY2018 revenue view $658.6 million -- Thomson Reuters I/B/E/S.  Full Article

Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​
Monday, 6 Nov 2017 03:49pm EST 

Nov 6 (Reuters) - Deerfield Management L.P: :Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​.  Full Article

Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"
Wednesday, 1 Nov 2017 06:53am EDT 

Nov 1 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​.Lannett - believe price-fixing allegations about a single product named in complaint that co sells are "meritless​".  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 06:52am EDT 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC
Monday, 2 Oct 2017 06:56am EDT 

Oct 2 (Reuters) - Lannett Company Inc : :Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC.Lannett Company Inc - co expect to commence marketing our prescription Lansoprazole delayed-release capsules product in next several months​.  Full Article

Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg
Wednesday, 27 Sep 2017 06:51am EDT 

Sept 27 (Reuters) - Lannett Company Inc :Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg.Lannett Company Inc - ‍Expect to commence marketing drug along with other approved products in next several months​.  Full Article

Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg
Tuesday, 26 Sep 2017 06:53am EDT 

Sept 26 (Reuters) - Lannett Company Inc :Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg.Lannett Company Inc - ‍Anticipates launching Dexmethylphenidate Hydrochloride tablets in next several months​.Lannett Company Inc - ‍Dexmethylphenidate Hydrochloride tablets are used for treatment of attention deficit and hyperactivity disorder ​.  Full Article

Lannett announces dismissal of class action lawsuit
Tuesday, 26 Sep 2017 06:40am EDT 

Sept 26 (Reuters) - Lannett Company Inc ::Lannett announces dismissal of class action lawsuit.Lannett Company - judge dismissed in entirety putative class action lawsuit against a multitude of generic drug manufacturers including Lannett​.  Full Article

Lannett's board of directors initiates CEO search
Monday, 25 Sep 2017 06:54am EDT 

Sept 25 (Reuters) - Lannett Company Inc ::Lannett's board of directors initiates CEO search.Lannett Company Inc - ‍board has retained a leading executive search firm to identify potential candidates to assume role of CEO​.Lannett Company Inc - during search process, Bedrosian will remain a member of board of directors.Lannett company - after appointment of successor, expected that Bedrosian to remain with co in strategic advisory role.Lannett Company-filed a 505(b)(2) new drug application with U.S. FDA for cocaine hydrochloride topical solution​.  Full Article

Lannett Company - ‍Arthur Bedrosian, CEO has prevailed in his lawsuit with U.S. Internal Revenue Service​
Friday, 22 Sep 2017 06:53am EDT 

Sept 22 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍Arthur Bedrosian, CEO has prevailed in his lawsuit with U.S. Internal Revenue Service​.Lannett-Judge found Bedrosian was credible,did not willfully fail to identify one of two foreign accounts on report of foreign bank,financial accounts.  Full Article

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance